Research The Bayer Scientific Magazin, Edition 28



Yüklə 11,94 Mb.
Pdf görüntüsü
səhifə1/21
tarix08.08.2018
ölçüsü11,94 Mb.
#61738
  1   2   3   4   5   6   7   8   9   ...   21


150 Jahre Bayer

Meilensteine eines Unternehmens –

Innovationen für die Zukunft

Helfer Natur

Biologischer 

Pflanzenschutz

Windenergie

Mehr Effizienz  

für Riesenrotoren

Medizin der Zukunft

Krebs und Herz-Kreislauf-Erkrankungen gezielt behandeln

Das Bayer-Forschungsmagazin

AUSGABE 25

Therapies to 

beat cancer

Unleashing the immune 

response to tumors 

Oncology:

Special feature: 

Tracking down 

 molecular clues

What metabolic profiles reveal 

about diseases

Virtual test 

systems

Using computer models 



for drug development

Protecting 

citrus trees

Strategies to control a 

bacterial disease

The Bayer Scientific Magazine



EDITION

 28 | July 2015


Point of view 

2

News in brief 



4

Interview with Management Board 

member Kemal Malik 

18

Masthead  



49

MEDICINE

Cover story:

Mobilizing the immune response 

to cancer

Immunotherapies in oncology 



10

Joint support for cancer research

Personalized medicine 



28

Enhancing immunity

Immunostimulants help 

animals fight infections 

34

Treatments for sick blood cells

Approaches for hemoglobin disorders  



42

AGRICULTURE

The wheat makers

Global strategies for in-demand cereal 



6

Profile

Insect toxicologist Dr. Ralf Nauen 



20

Yellow dragon in the orange grove

Strategies against citrus greening 



44

Cotton

All-round protection for quality fibers 



48

DOSSIER

Virtual tests for new therapies

Computer models support 

drug development 

36

SPECIAL FEATURE

Decoding molecular patterns

Tracking down diseases with biomarkers 



30

FOUNDATIONS

Bayer foundations promote science,

medicine and social innovation 

24

Innovations from Bayer have helped millions of people around the world. 

We are the only major company worldwide that simultaneously addresses the 

health of humans, animals and plants. This is important because all three share 

great similarities; many mechanisms are comparable, particularly at the molec-

ular level where our active substances are effective. Our core expertise involves 

creating molecules that can positively influence these biochemical processes in 

living organisms.

In the future, we will need innovations more than ever before. But as an inno-

vation company, we need trust and a healthy risk culture. We need a societal 

environment that is amenable to novel solutions. In many regions of the world

robust and high-yielding cereal varieties represent desperately needed progress. 

In other countries, by contrast, we have to overcome issues such as demographic 

change. Only with innovations, implemented with courage and creativity, can we 

offer appropriate solutions to the many different challenges facing our society. 

This is what “Bayer: Science For A Better Life” stands for.

As a Life Science company, we also want to intensify the dialog with the 

 general public and thus help to bridge the gap between public perception and the 

real significance of innovation. That will require information, transparency and a 

greater understanding of innovations. We hope that this edition of research will 

serve as a positive contribution to the debate.

We have to make the benefits 

of innovation even clearer

Best regards,

Dr. Marijn Dekkers, Chairman of the Board of Management of Bayer AG



Dear reader,

EDITORIAL




Dossier: Computer models in medicine 

36

Special feature



Cancer researchers are aiming to selectively enhance the immune system 

to enable the human body to successfully combat tumor diseases. Bayer 

employees like Dr. Volker Müller (photo above) and Charlene Becker (small 

photo) are collaborating in research teams with international oncology 

experts to develop novel immunotherapies that could even help  

patients at an advanced stage of the disease in future.                                

10

During drug development, Bayer’s scientists use computer-supported pre-



diction software and virtual patients to analyze the precise path that active 

ingredients take in the body. For example, they can predict the effect that 

the liver has on drug candidates.

Cover story



Mobilizing the immune response 

to cancer

Bayer foundations  24

The Bayer Cares Foundation invests in social inno-

vations. The Bayer Science & Education Foundation 

promotes projects in the fields of life science and 

medicine, such as the educational initiative launched 

by the NCL Foundation which teaches senior high 

school classes about childhood dementia.

The wheat makers 

6

The global demand for wheat is increasing. Bayer 

researchers like Céline Zimmerli and Guillaume Plé 

(left to right) are working on the development of 

more robust and high-yielding varieties in a global 

alliance network.



Citrus fruits at risk  44

Citrus greening disease causes dramatic harvest losses 

on citrus plantations. Bayer scientists are developing 

integrated strategies to combat the bacterial disease 

and the insect that transmits it.

Dr. Julian I. Borissoff and Dr. Mark-Christoph Ott 

(left to right) are investigating metabolic 

 processes in the organism with the objective of 

finding new targets for drug products and  

crop protection agents                                         

30

Photos: Ingo Rapper



s/WiW

o (1), P


eter Ginter/Bayer AG (4), Martin Zimelka/Bayer AG (1), Mar

cus Müller-Sar

an (1), Gettyimages (1)

Metabolomics

CONTENTS 

Bayer research 28    July 2015

1



Yüklə 11,94 Mb.

Dostları ilə paylaş:
  1   2   3   4   5   6   7   8   9   ...   21




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©genderi.org 2024
rəhbərliyinə müraciət

    Ana səhifə